FORA Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

FORA Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.34M	Buy	+2,147	New	+$1.46M	0.09%	197
2025 Q4	–	Sell	-564	Closed	-$317K	–	614
2025 Q3	$317K	Sell	564 -2,503	-82%	-$1.42M	0.06%	362
2025 Q2	$1.61M	Sell	3,067 -2,380	-44%	-$1.33M	0.18%	150
2025 Q1	$3.45M	Buy	5,447 +2,894	+113%	+$1.99M	0.35%	89
2024 Q4	$1.82M	Buy	2,553 +1,369	+116%	+$1.15M	0.21%	145
2024 Q3	$1.24M	Sell	1,184 -4,229	-78%	-$4.71M	0.15%	185
2024 Q2	$5.69M	Sell	5,413 -1,911	-26%	-$1.85M	0.69%	35
2024 Q1	$7.05M	Buy	+7,324	New	+$6.96M	0.58%	48
2023 Q4	–	Sell	-8,244	Closed	-$6.78M	–	607
2023 Q3	$6.78M	Buy	+8,244	New	+$6.48M	0.6%	44
2023 Q2	–	Sell	-9,504	Closed	-$7.81M	–	577
2023 Q1	$7.81M	Buy	+9,504	New	+$7.17M	0.78%	29
2022 Q4	–	Sell	-7,204	Closed	-$4.96M	–	631
2022 Q3	$4.96M	Buy	+7,204	New	+$4.53M	0.95%	18
2022 Q2	–	Sell	-5,250	Closed	-$3.63M	–	646
2022 Q1	$3.63M	Buy	+5,250	New	+$3.32M	0.66%	29
2021 Q4	–	Sell	-5,006	Closed	-$3.03M	–	435
2021 Q3	$3.03M	Buy	5,006 +1,306	+35%	+$811K	0.76%	32
2021 Q2	$2.07M	Buy	+3,700	New	+$1.87M	0.38%	63
2021 Q1	–	Sell	-281	Closed	-$136K	–	1040
2020 Q4	$136K	Buy	+281	New	+$152K	0.02%	589
2020 Q1	–	Sell	-5,278	Closed	-$1.98M	–	1282
2019 Q4	$1.98M	Buy	+5,278	New	+$1.78M	0.2%	132

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

FORA Capital's REGN Position: Q2 2026 in Review

FORA Capital opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 2,147 shares worth $1.34M. The stake represents 0.09% of the portfolio and ranks #197 among its holdings. This is a return to the name: FORA Capital previously reported a position in REGN as recently as Q3 2025.

FORA Capital first reported a position in REGN in Q4 2019 and has held it in 16 quarters since. The position peaked at $7.81M in Q1 2023. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

FORA Capital held 2,147 shares of Regeneron Pharmaceuticals worth $1.34M as of Q2 2026.
Regeneron Pharmaceuticals was a new FORA Capital position in Q2 2026.
Regeneron Pharmaceuticals made up 0.09% of FORA Capital's portfolio in Q2 2026, its #197 holding.
FORA Capital first reported a position in Regeneron Pharmaceuticals in Q4 2019 and has held it in 16 quarters since.
FORA Capital's Regeneron Pharmaceuticals position peaked at $7.81M in Q1 2023.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on FORA Capital's 13F filing for Q2 2026, filed 13 Aug 2026.